Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
Top-Rated Stocks  
NASDAQ:NTRA

Natera - NTRA Stock Forecast, Price & News

$37.58
+0.35 (+0.94%)
(As of 11/25/2022 08:58 PM ET)
Add
Compare
Today's Range
$36.68
▼
$37.66
50-Day Range
$34.17
▼
$48.93
52-Week Range
$26.10
▼
$99.63
Volume
451,600 shs
Average Volume
1.73 million shs
Market Capitalization
$3.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$83.82

Natera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
123.0% Upside
$83.82 Price Target
Short Interest
Bearish
6.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Natera in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$797,832 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.68) to ($4.77) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

618th out of 1,044 stocks

Medical Laboratories Industry

18th out of 25 stocks

See Top Rated MarketRank™ Stocks Here
NTRA stock logo

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Stock News Headlines

November 23, 2022 | finance.yahoo.com
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022 | finance.yahoo.com
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
November 18, 2022 | americanbankingnews.com
Natera (NASDAQ:NTRA) PT Lowered to $67.00
November 18, 2022 | americanbankingnews.com
Natera, Inc. (NASDAQ:NTRA) Receives $82.64 Average Target Price from Brokerages
November 10, 2022 | finance.yahoo.com
Natera Third Quarter 2022 Earnings: Beats Expectations
November 8, 2022 | finance.yahoo.com
Natera Reports Third Quarter 2022 Financial Results
November 4, 2022 | finance.yahoo.com
Natera (NTRA) Shares Outperformed in the Third Quarter on Positive Business Updates
November 2, 2022 | finance.yahoo.com
Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs
November 1, 2022 | finance.yahoo.com
Natera to Report its Third Quarter 2022 Results on November 8th
November 1, 2022 | finance.yahoo.com
Natera to Participate in Credit Suisse 31st Annual Healthcare Conference
October 26, 2022 | finance.yahoo.com
Natera, Inc. (NTRA)
October 17, 2022 | nasdaq.com
NTRA December 16th Options Begin Trading - Nasdaq
October 12, 2022 | proactiveinvestors.com
Naturally Splendid says Denny's renews agreement to provide Plantein plant-based Nuggets and Crumbed Tenders at all its restaurants across Canada - Proactive Investors USA
October 11, 2022 | seekingalpha.com
Natera: Cracks In The Bearish Trade
October 10, 2022 | reuters.com
Quest Diagnostics agrees to settlement of DNA-test patent dispute - Reuters
October 6, 2022 | finance.yahoo.com
New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
October 4, 2022 | seekingalpha.com
Natera gains on publication of data on transplant rejection assessment test (NASDAQ:NTRA) - Seeking Alpha
October 4, 2022 | streetinsider.com
Natera (NTRA) Reports Study Showing Prospera Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection - StreetInsider.com
September 29, 2022 | finance.yahoo.com
Natera Announces 2025 ESG Goals with Publication of 2021 Report
September 12, 2022 | benzinga.com
Natera (NASDAQ:NTRA) – Natera Presents New Colorectal And Breast Cancer Data From The CIRCULATE-Japan Stu - Benzinga
September 12, 2022 | finance.yahoo.com
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
September 8, 2022 | reuters.com
NTRA.O - Natera Inc | Stock Price & Latest News | Reuters
September 6, 2022 | benzinga.com
Natera Inc (NTRA) – Natera to Participate in Upcoming Investor Conferences - Benzinga
September 5, 2022 | nasdaq.com
Is Natera (NASDAQ:NTRA) Using Too Much Debt? - Nasdaq
September 1, 2022 | finance.yahoo.com
Hereditary Testing Market (Size, Volume, Share & Trends) — Report Comparison by Rating, ToC, Page Count, and Price only at Douglas Insights - Yahoo Finance
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings
11/04/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTRA
CUSIP
N/A
CIK
1604821
Web
www.natera.com
Phone
(650) 249-9090
Fax
N/A
Employees
2,670
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$83.82
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+123.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-471,720,000.00
Net Margins
-70.34%
Pretax Margin
-70.27%
Return on Equity
-109.07%
Return on Assets
-48.98%

Debt

Debt-to-Equity Ratio
0.78
Current Ratio
3.10
Quick Ratio
2.95

Sales & Book Value

Annual Sales
$625.49 million
Price / Sales
5.86
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.70 per share
Price / Book
10.16

Miscellaneous

Outstanding Shares
97,603,000
Free Float
87,579,000
Market Cap
$3.67 billion
Optionable
Optionable
Beta
1.33

Key Executives

  • Dr. Matthew Rabinowitz Ph.D.Dr. Matthew Rabinowitz Ph.D. (Age 49)
    Co-Founder & Exec. Chairman
    Comp: $502.21k
  • Mr. Steven Leonard ChapmanMr. Steven Leonard Chapman (Age 43)
    CEO, Pres & Director
    Comp: $925.59k
  • Mr. Michael B. Brophy M.B.A. (Age 42)
    Chief Financial Officer
    Comp: $661.5k
  • Mr. Robert A. SchuerenMr. Robert A. Schueren (Age 60)
    Chief Operating Officer
    Comp: $706.72k
  • Mr. Daniel Rabinowitz L.L.M.Mr. Daniel Rabinowitz L.L.M. (Age 53)
    LL.M., Sec. & Chief Legal Officer
    Comp: $557.47k
  • Mr. Jonathan Sheena M.Eng.Mr. Jonathan Sheena M.Eng. (Age 49)
    Co-Founder & Director
  • Ms. Olesya A. Anisimova CPA
    Chief Accounting Officer
  • Mr. Rishi Kacker
    Chief Technology Officer
  • Mr. Eric A. Evans
    Chief Scientific Officer
  • Mr. Phil Grinnell
    VP of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.

What is Natera's stock price forecast for 2023?

6 analysts have issued 1 year price objectives for Natera's stock. Their NTRA share price forecasts range from $55.00 to $110.00. On average, they predict the company's share price to reach $83.82 in the next year. This suggests a possible upside of 123.0% from the stock's current price.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2022?

Natera's stock was trading at $93.39 at the start of the year. Since then, NTRA stock has decreased by 59.8% and is now trading at $37.58.
View the best growth stocks for 2022 here.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NTRA earnings forecast.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($1.63) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by $0.36. The medical research company had revenue of $158.10 million for the quarter, compared to the consensus estimate of $151.92 million. Natera had a negative net margin of 70.34% and a negative trailing twelve-month return on equity of 109.07%. Natera's quarterly revenue was up 61.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.72) earnings per share.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $810.00 million-$830.00 million, compared to the consensus revenue estimate of $819.07 million.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fred Alger Management LLC (9.00%), Vanguard Group Inc. (8.52%), State Street Corp (2.88%), Samlyn Capital LLC (2.33%), RTW Investments LP (2.26%) and Kynam Capital Management LP (2.07%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $37.58.

How much money does Natera make?

Natera (NASDAQ:NTRA) has a market capitalization of $3.67 billion and generates $625.49 million in revenue each year. The medical research company earns $-471,720,000.00 in net income (profit) each year or ($5.68) on an earnings per share basis.

How many employees does Natera have?

The company employs 2,670 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 11/28/2022 by MarketBeat.com Staff